CHOP Researchers Define Seizure Burden, Developmental Outcomes for STXBP1-Related Disorders
Published on
This major step allows for the creation of clinical trials to test key endpoints that will determine the efficacy of new therapies.
Published on
This major step allows for the creation of clinical trials to test key endpoints that will determine the efficacy of new therapies.
Published on
Dravet syndrome is a severe neurodevelopmental disorder defined by treatment-resistant epilepsy and features related to autism spectrum disorder.
Published on
Findings demonstrate how a new computational method could effectively analyze phenotypes and identify similarities among patient populations.
Published on
STXBP1-related disorders include gastrointestional and respiratory symptoms in certain patients, according to extensive interviews with caregivers.
Published on
A $25 million gift from an anonymous donor to Penn Medicine and Children’s Hospital of Philadelphia (CHOP) will establish the Center for Epilepsy and Neurodevelopmental Disorders (ENDD), accelerating collaborative research in genetic therapies for neurodevelopmental disorders.
Published on
Patients with the identified variant may respond favorably to targeted treatment with a readily available anti-seizure medication.
Published on
Certain patients were more likely to use telemedicine even with the reopening of in-person appointments, while barriers to telemedicine remained for some families.
Published on
While telemedicine appeared to be effective in 95% of cases, some younger patients and those with neuromuscular disorders still required in-person visits.
Published on
Unique endocrinology-neurology collaboration seeks to understand the variation in seizure activity in patients with hyperinsulinism/hyperammonemia.
Published on
Unique endocrinology-neurology collaboration seeks to understand the variation in seizure activity in patients with hyperinsulinism/hyperammonemia.